What is the recommended steroid therapy regimen for pediatric nephrotic syndrome, including dosing, tapering, and management of steroid‑resistant or frequently relapsing disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Steroid Therapy in Pediatric Nephrotic Syndrome

For the initial episode of pediatric nephrotic syndrome, start oral prednisone at 60 mg/m²/day (maximum 60 mg) as a single daily dose for 6 weeks, followed by 40 mg/m²/dose on alternate days for another 6 weeks with tapering, for a total treatment duration of 12-16 weeks. 1, 2

Initial Episode Treatment Protocol

Daily Phase (Weeks 1-6)

  • Dose: 60 mg/m²/day OR 2 mg/kg/day (maximum 60 mg/day) 1
  • Timing: Single morning dose (preferred over divided doses) 1, 3
  • Duration: 6 weeks of daily therapy 2

Key Evidence: Single daily dosing causes significantly less hypothalamic-pituitary-adrenal (HPA) axis suppression compared to divided doses (83% vs 100% suppression), with similar remission rates but longer time to first relapse 3. The 2025 KDIGO guideline strongly recommends either 8 weeks (4+4) or 12 weeks (6+6) total duration 4.

Alternate-Day Phase (Weeks 7-12)

  • Dose: 40 mg/m²/dose OR 1.5 mg/kg/dose (maximum 40 mg on alternate days) 1
  • Duration: 6 weeks 2
  • Tapering: After 6 weeks alternate-day, taper by 10 mg/m²/week until reaching 5 mg on alternate days 2
  • Total duration: 16 weeks including taper 2

Critical Point: Longer initial therapy (≥12 weeks total) reduces relapse risk compared to shorter courses (RR 0.73,95% CI 0.60-0.89) 5. However, recent 2026 meta-analysis shows that cumulative prednisolone dose (≥3.135 g/m²) and age at onset (≥2.5 years) are stronger predictors of outcomes than duration alone 6.

Management of Relapses

Infrequent Relapses

  • Daily phase: 60 mg/m²/day (maximum 60 mg) until remission (urine dipstick trace/negative for ≥3 consecutive days) 1, 2
  • Alternate-day phase: 40 mg/m²/dose on alternate days for at least 4 weeks 1, 7

Frequent Relapses (FR) and Steroid-Dependent (SD) Disease

Treatment of acute relapse:

  • 60 mg/m²/day until remission (≥3 days) 1, 2
  • Then 40 mg/m²/dose on alternate days for 1 week
  • Taper by 10 mg/m²/week to complete 4 weeks total 2

Important Update: The 2025 KDIGO guideline now recommends AGAINST routinely giving daily glucocorticoids during upper respiratory infections to prevent relapses (Grade 1C) 4. This reverses previous practice based on the PREDNOS2 trial showing no benefit of prophylactic steroids during infections.

Steroid-Sparing Agents

Introduce steroid-sparing agents when: 1, 4

  • Frequently relapsing disease with serious glucocorticoid-related adverse effects
  • ALL cases of steroid-dependent nephrotic syndrome
  • Significant steroid toxicity develops

First-Line Options (in order of preference):

  1. Levamisole (if available): First-line for frequent relapses 2

  2. Cyclophosphamide:

    • Oral: 2 mg/kg/day for 8-12 weeks (maximum cumulative 168 mg/kg) 1
    • IV: 500 mg/m²/dose monthly for 4 months 2
    • Must achieve remission with steroids before starting 1
    • Preferred for FR disease (Grade 1B); suggested for SD disease (Grade 2C) 1

  3. Calcineurin Inhibitors (CNIs):

    • Use if cyclophosphamide fails or contraindicated
    • Stop if no partial remission at 6 months 2

  4. Mycophenolate Mofetil: Up to 1g twice daily 1

  5. Rituximab: Increasingly used, particularly for SD disease 4

Critical Sequencing: Alkylating agents (cyclophosphamide/chlorambucil) should be used BEFORE cyclosporine as they have curative potential, while CNIs only maintain remission 5.

Steroid-Resistant Nephrotic Syndrome (SRNS)

Definition: No remission after minimum 8 weeks of corticosteroid therapy 2

Immediate actions:

  • Confirm diagnosis at 6 weeks if no response 2
  • Obtain renal biopsy (Grade A, strong recommendation) 2
  • Consider genetic testing (Grade B) 2
  • Start CNI if biopsy not readily available 2

Common Pitfalls to Avoid

  1. Dosing in overweight children: Use ideal body weight, not actual weight; consider maximum 80 mg daily dose 7

  2. Premature introduction of steroid-sparing agents: Ensure adequate initial steroid course (12-16 weeks) before labeling as frequently relapsing 1, 4

  3. Divided-dose steroids: Avoid unless specifically indicated—single morning dose reduces HPA suppression 3

  4. Prophylactic steroids during infections: No longer recommended routinely 4

  5. Starting cyclophosphamide during active disease: Must achieve remission with steroids first 1

  6. Inadequate initial therapy duration: Shorter courses (<12 weeks) significantly increase relapse risk 5, 6

Monitoring Requirements

  • Daily: Urine dipstick during active disease
  • Remission definition: Urine protein trace/negative for ≥3 consecutive days 2
  • HPA axis: Consider testing after 6 weeks of daily steroids, especially with divided dosing 3
  • On CNIs: Monitor for nephrotoxicity; stop if no partial remission at 6 months 2

References

5
Research

Treatment of nephrotic syndrome in children and controlled trials.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2003

Related Questions

What is the appropriate prednisolone dose for nephrotic syndrome?
Why does diuresis occur after initiating prednisolone therapy in nephrotic syndrome?
What is the appropriate prednisolone dosing regimen, including once‑daily versus twice‑daily administration and the taper schedule duration?
What is the recommended steroid dosing regimen for a child with primary nephrotic syndrome or a nephritic presentation (e.g., rapidly progressive glomerulonephritis)?
How soon does prednisone wear off after a 9 am dose?
What is the appropriate management for deflated bloodlines during hemodialysis?
Can a 120‑mg tablet of fexofenadine (Allegra) be added to manage the rash or pruritus associated with pegfilgrastim therapy?
What immediate steps should I take for a child presenting with nasal flaring and tachypnea?
For a low‑risk patient with LDL‑C 117 mg/dL and triglycerides 507 mg/dL, should treatment begin with a fibrate or a statin?
When should thiamine (vitamin B1) be prescribed instead of vitamin B12 (cobalamin) tablets, and what are the recommended dosing regimens for each?
For a patient with standard cardiovascular risk, what is the target LDL‑cholesterol level?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.